BR9608558A - Processos e usos de fator de crescimento de tecido conjuntivo como um agente de indução - Google Patents

Processos e usos de fator de crescimento de tecido conjuntivo como um agente de indução

Info

Publication number
BR9608558A
BR9608558A BR9608558-4A BR9608558A BR9608558A BR 9608558 A BR9608558 A BR 9608558A BR 9608558 A BR9608558 A BR 9608558A BR 9608558 A BR9608558 A BR 9608558A
Authority
BR
Brazil
Prior art keywords
ctgf
growth factor
connective tissue
tissue growth
inducing agent
Prior art date
Application number
BR9608558-4A
Other languages
English (en)
Inventor
Gary R Grotendorst
Original Assignee
Gary R Grotendorst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gary R Grotendorst filed Critical Gary R Grotendorst
Publication of BR9608558A publication Critical patent/BR9608558A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)

Abstract

Patente de Invenção: <B>"PROCESSOS E USOS DE FATOR DE CRESCIMENTO DE TECIDO CONJUNTIVO COMO UM AGENTE DE INDUçãO"<D>. A presente invenção refere-se a novos processos e composições relacionados à administração de fator de crescimento de tecido conjuntivo, sozinho ou em combinação com outros fatores de crescimento, composições ou compostos, para induzir a formação de tecido conjuntivo, incluindo osso, cartilagem e a pele.
BR9608558-4A 1995-06-02 1996-05-31 Processos e usos de fator de crescimento de tecido conjuntivo como um agente de indução BR9608558A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/459,717 US5770209A (en) 1991-08-30 1995-06-02 Acceleration of wound healing using connective tissue growth factor
PCT/US1996/008210 WO1996038168A1 (en) 1995-06-02 1996-05-31 Methods and uses of connective tissue growth factor as an induction agent

Publications (1)

Publication Number Publication Date
BR9608558A true BR9608558A (pt) 1999-11-30

Family

ID=23825885

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9609521A BR9609521A (pt) 1995-06-02 1996-05-31 Fator de crescimento de tecido conectivo
BR9608558-4A BR9608558A (pt) 1995-06-02 1996-05-31 Processos e usos de fator de crescimento de tecido conjuntivo como um agente de indução

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9609521A BR9609521A (pt) 1995-06-02 1996-05-31 Fator de crescimento de tecido conectivo

Country Status (11)

Country Link
US (4) US5770209A (pt)
EP (2) EP0831903B1 (pt)
JP (4) JPH11507332A (pt)
CN (2) CN1191491A (pt)
AT (1) ATE464067T1 (pt)
AU (2) AU720268B2 (pt)
BR (2) BR9609521A (pt)
CA (2) CA2222609A1 (pt)
DE (1) DE69638162D1 (pt)
SG (1) SG108208A1 (pt)
WO (2) WO1996038172A1 (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US7384634B2 (en) 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US7026299B2 (en) 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
AU763649B2 (en) * 1995-06-02 2003-07-31 University Of South Florida Connective tissue growth factor
US6790606B1 (en) 1996-03-15 2004-09-14 Munin Corporation Extracellular matrix signaling molecules
US20090081228A1 (en) * 1996-03-15 2009-03-26 Munin Corporation Cyr61 compositions and methods
US7521540B2 (en) * 1996-03-15 2009-04-21 Munin Corporation CYR61 compositions and methods
DK0888452T3 (da) 1996-03-15 2004-06-14 Munin Corp Human CYR61, et ekstracellulært matrix-signalmolekyle
AU7610396A (en) * 1996-11-08 1998-06-03 Human Genome Sciences, Inc. Connective tissue growth factor-3
US20040132987A1 (en) 1996-11-08 2004-07-08 Human Genome Sciences, Inc. Connective tissue growth factor-3
DE69734395T2 (de) * 1996-12-06 2006-07-27 Osiris Therapeutics, Inc. Verbesserte chondrogene differenzierung von menschlichen mesenchym-stammzellen
DE19719652A1 (de) * 1997-05-09 1998-12-03 Merckle Gmbh Tissue-Faktor zur Förderung von Wundheilung
WO1998057976A1 (en) * 1997-06-19 1998-12-23 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AU7980598A (en) * 1997-06-19 1999-01-04 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a growth factor-like protein (as amended)
US5876730A (en) * 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
JP4537507B2 (ja) * 1997-12-25 2010-09-01 アムジェン インコーポレイテッド 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
WO1999033878A1 (en) 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US6451771B1 (en) 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
ES2338946T3 (es) * 1998-02-13 2010-05-13 Nutramax Laboratories, Inc. Agentes y procedimientos para la proteccion, tratamiento y reparacion del tejido conjuntivo.
US20070141181A1 (en) 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6797289B2 (en) * 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
EP1112088B1 (en) 1998-09-08 2010-10-27 Henry Ford Health System Method for detecting connective tissue growth factor for diagnosing a renal disorder
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
DK1140969T3 (da) * 1998-12-14 2007-09-17 Univ Miami Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US6350472B1 (en) * 1998-12-14 2002-02-26 Steinbach, Pylant, And Hermann, L.L.C. Method of treating HIV infection with transdermal gel containing mammalian liver extract
CN101385851A (zh) * 1999-02-01 2009-03-18 遗传研究所公司 用于关节软骨愈合和修复的方法和组合物
US6537755B1 (en) * 1999-03-25 2003-03-25 Radoje T. Drmanac Solution-based methods and materials for sequence analysis by hybridization
AU6929500A (en) 1999-08-27 2001-03-26 Fibrogen, Inc. Connective tissue growth factor receptor, its agonists and antagonists, and their therapeutic and diagnostic uses
US20060052328A1 (en) * 2000-07-11 2006-03-09 Human Genome Sciences, Inc. Connective tissue growth factor-2
CA2412124A1 (en) * 2000-07-11 2002-01-17 Transgene S.A. Connective tissue growth factor-2
US6939540B1 (en) * 2000-07-31 2005-09-06 Cornell Research Foundation, Inc. Method of enhancing bone density
US6599526B2 (en) * 2000-08-18 2003-07-29 The University Of North Texas Health Science Center At Fort Worth Pericardial anti-adhesion patch
EP1354947A4 (en) * 2000-11-22 2005-01-19 Yamanouchi Pharma Co Ltd NEW POLYPEPTIDE
US20030113816A1 (en) * 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
PL371977A1 (en) * 2001-09-24 2005-07-11 Verigen Ag Autologous growth factor cocktail composition, method of production and use
JP4456796B2 (ja) * 2001-09-27 2010-04-28 株式会社林原生物化学研究所 コラーゲン産生増強剤の製造方法とその用途
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
JP2005512579A (ja) * 2001-12-12 2005-05-12 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 心臓傷害からの心臓保護のためのトリステトラプロリンの阻害
EP1925306A3 (en) 2002-04-30 2008-09-17 Alcon, Inc. Agents which Regulate, Inhibit, or Modulate the Activity and/or Expression of Connective Tissue Growth Factor (CTGF) to Lower Intraocular Pressure
WO2003092584A2 (en) * 2002-04-30 2003-11-13 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2004099372A2 (en) * 2003-05-01 2004-11-18 University Of Florida Anti-scarring ribozymes and methods
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20050153395A1 (en) * 2003-09-29 2005-07-14 Children's Hospital Inc. Unique integrin binding site in connective tissue growth factor (CTGF)
EP1687410A4 (en) * 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc ANTISENSE OLIGONUCLEOTIDE OPTIMIZED FOR KIDNEY TARGETING
US20050191653A1 (en) * 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2005077413A1 (en) 2004-02-11 2005-08-25 Fibrogen, Inc. Ctgf as target for the therapy of diabetic nephropathy
CA2565070A1 (en) 2004-04-28 2005-11-24 Fibrogen, Inc. Anti-ctgf agents for the treatment of pancreatic cancer
WO2005120231A1 (en) * 2004-06-08 2005-12-22 Fibrogen, Inc. Connective tissue growth factor regulates intracellular signaling pathways
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders
AU2006244148A1 (en) 2005-05-05 2006-11-16 Fibrogen, Inc. Cardiovascular disease therapies
US20110244006A1 (en) * 2007-11-29 2011-10-06 The Trustees Of Columbia University In The City Of New York Microsphere skin treatment
US20100331249A1 (en) * 2008-07-23 2010-12-30 National Taiwan University Pharmaceutical composition for inhibiting peritoneal dissemination
NZ601660A (en) 2008-08-25 2014-05-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
CA2746527A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
EP2221387A1 (en) 2009-02-19 2010-08-25 Université de la Méditerranée Fibrosis susceptibility gene and uses thereof
JP5166360B2 (ja) * 2009-06-23 2013-03-21 株式会社島津製作所 マイクロ反応装置を用いた細胞運動評価方法
EP2448971A1 (en) 2009-07-02 2012-05-09 Fibrogen, Inc. Methods for treatment of muscular dystrophy
US20120244169A1 (en) 2009-11-06 2012-09-27 Fibrogen, Inc. Treatment for Radiation-Induced Disorders
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
BR112012024049A2 (pt) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp interferência de rna em indicações dérmicas e fibróticas
KR101249041B1 (ko) 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
US20140134181A1 (en) 2010-11-05 2014-05-15 Kenneth E. Lipson Treatment Method For Lung Remodeling Diseases
US9102721B2 (en) 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
KR101697396B1 (ko) 2011-02-02 2017-01-17 엑스칼리아드 파마슈티컬즈, 인코포레이티드 결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
CN104302780B (zh) 2011-08-05 2017-04-12 艾克斯-马赛大学 纤维变性易感性il22ra2基因及其用途
ES2718472T3 (es) 2012-05-03 2019-07-02 Fibrogen Inc Métodos para tratar fibrosis pulmonar idiopática
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
KR20250162599A (ko) * 2018-11-08 2025-11-18 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 부착 비의존성 세포 및 그 용도
CN115925926A (zh) 2019-06-04 2023-04-07 江苏恒瑞医药股份有限公司 抗结缔组织生长因子抗体及其应用
MX2022003768A (es) * 2019-10-03 2022-08-19 Vitruvia Holdings Inc Metodo de restauracion del tejido conectivo.
US12472234B2 (en) 2021-09-10 2025-11-18 Bjorn Eek Treatment of connective tissue injuries
JP2023129339A (ja) * 2022-03-02 2023-09-14 イーク ビョルン 結合組織損傷の治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1989A (en) 1841-02-20 Stump-extractor
US5356630A (en) * 1989-02-22 1994-10-18 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5149691A (en) * 1991-03-12 1992-09-22 Creative Biomolecules, Inc. Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone
FR2678283A1 (fr) * 1991-06-25 1992-12-31 Centre Nat Rech Scient Sequences de nucleotides, sequences d'acides amines correspondantes, et leurs applications biologiques.
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
IL105529A0 (en) * 1992-05-01 1993-08-18 Amgen Inc Collagen-containing sponges as drug delivery for proteins

Also Published As

Publication number Publication date
AU720268B2 (en) 2000-05-25
EP0831885A4 (en) 2000-11-29
AU722919B2 (en) 2000-08-17
EP0831903A4 (en) 2001-02-28
EP0831903B1 (en) 2010-04-14
JPH11507332A (ja) 1999-06-29
EP0831903A1 (en) 1998-04-01
EP0831885A1 (en) 1998-04-01
JP2007051150A (ja) 2007-03-01
CA2222609A1 (en) 1996-12-05
JP2004132974A (ja) 2004-04-30
US6150101A (en) 2000-11-21
CA2222509C (en) 2012-12-04
MX9709294A (es) 1998-08-30
AU5958296A (en) 1996-12-18
US6069006A (en) 2000-05-30
WO1996038172A1 (en) 1996-12-05
CN1195295A (zh) 1998-10-07
ATE464067T1 (de) 2010-04-15
BR9609521A (pt) 1999-06-15
US5770209A (en) 1998-06-23
AU5885596A (en) 1996-12-18
CN1191491A (zh) 1998-08-26
SG108208A1 (en) 2005-01-28
WO1996038168A1 (en) 1996-12-05
CA2222509A1 (en) 1996-12-05
JPH11506449A (ja) 1999-06-08
US6232064B1 (en) 2001-05-15
DE69638162D1 (de) 2010-05-27

Similar Documents

Publication Publication Date Title
BR9608558A (pt) Processos e usos de fator de crescimento de tecido conjuntivo como um agente de indução
US5416192A (en) Epithelins: novel cysteine-rich growth modulating proteins
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
UY24255A1 (es) Anticuerpos monoclonales de alta afinidad neutralizadores especificos para la f-proteina rsv y metodos para su fabricacion y uso terapeutico de los mismos.
EA200000325A1 (ru) Способ доставки генов в антиген-презентирующие клетки кожи
DE69836630D1 (de) Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
DE69005352D1 (de) Antikörper enthaltende Verabreichungssysteme für biologische verhaltensändernde Stoffe.
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
ES2058908T3 (es) Procedimiento para la separacion y purificacion de sialil-transferasas.
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
AU5720498A (en) Chemical synthesis of nucleosides analogs and their incorporation into polynucleotides
NO20030495D0 (no) Peptider som presenteres av celler
BR9713450A (pt) Quimiocinas de mamìfero
WO1995011919A3 (de) REKOMBINANTE PilC-PROTEINE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG
EP1655382A3 (en) Colon specific gene and protein
BR9914492A (pt) Polipeptìdos basb034 de moraxella catarrhalis e usos dos mesmos
BR9911609A (pt) Proteìnas e genes de moraxella catarrhalis, antìgenos, anticorpos e usos
PT914417E (pt) Dnase ii humana
WO1998041538A3 (en) Novel human cytokine/steroid receptor protein
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
Wang Molecular studies of sensory axon collateral development
EP1496065A3 (en) Breast specific genes and proteins
ES2125202A1 (es) Adn recombinante que codifica para epitopos del alergeno profilina util para el diagnostico y tratamiento de alergias.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law